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Abstract
Background: Cognitive behavioural therapy (CBT) has been shown to improve outcomes for patients with fibromyalgia,
and its cardinal feature chronic widespread pain (CWP). Prediction models have now been developed which identify
groups who are at high-risk of developing CWP. It would be beneficial to be able to prevent the development of CWP in
these people because of the high cost of symptoms and because once established they are difficult to manage. We will
test the hypothesis that among patients who are identified as at high-risk, a short course of telephone-delivered CBT
(tCBT) reduces the onset of CWP. We will further determine the cost-effectiveness of such a preventative intervention.
Methods: The study will be a two-arm randomised trial testing a course of tCBT against usual care for prevention of
CWP. Eligible participants will be identified from a screening questionnaire sent to patients registered at general practices
within three Scottish health boards. Those returning questionnaires indicating they have visited their doctor for regional
pain in the last 6 months, and who have two of, sleep problems, maladaptive behaviour response to illness, or high
number of somatic symptoms, will be invited to participate. After giving consent, participants will be randomly allocated
to either tCBT or usual care. We aim to recruit 473 participants to each treatment arm. Participants in the tCBT group will
have an initial assessment with a CBT therapist by telephone, then 6 weekly sessions, and booster sessions 3 and
6 months after treatment start. Those in the usual care group will receive no additional intervention. Follow-up
questionnaires measuring the same items as the screening survey questionnaire will be sent 3, 12 and 24 months after
start of treatment. The main outcome will be CWP at the 12 month questionnaire.
Discussion: This will be the first trial of an intervention aimed at preventing fibromyalgia or CWP. The results of the study
will help to inform future treatments for the prevention of chronic pain, and aetiological models of its development.
Trial registration: ClinicalTrials.gov ID: NCT02668003URL: Please check that the following URLs are working. If not, please
provide alternatives: NCT02668003Alternative is: https://www.clinicaltrials.gov/ct2/show/NCT02668003>. Date registered:
28-Jan-2016.
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Background
Chronic widespread pain (CWP), the cardinal feature of
fibromyalgia, is associated with lost work productivity,
psychological ill health, and poor quality of life. It is one of
the most common reasons for referral to a rheumatologist
[1]. The cost of CWP is high in terms of both individual,
societal and health costs: for example, in the United States,
mean per-patient costs (including pain and non–pain-re-
lated medication, physician consultations, tests and proce-
dures, and emergency department visits) in the 6 months
following a new diagnosis of fibromyalgia have been re-
ported as $3481, comparable to patients with rheumatoid
arthritis [2] but resulting in worse quality of life [3]. Current
guidelines recommend pharmacological, physical, and psy-
chological therapies although the importance attributed to
individual therapies is inconsistent [4]. There is good evi-
dence for musculoskeletal pain conditions generally that
the longer the duration of symptoms, the less likely that
symptoms are to improve [5, 6], including with specific
interventions [7, 8]. This is particularly so for CWP which,
once developed, is challenging to manage and effect
improvement.
A systematic review and meta-analysis of randomised
controlled trials (RCT) of Cognitive Behaviour Therapy
(CBT) for patients with fibromyalgia concluded that CBT
improves coping with pain, reduces depressed mood and
Fig. 1 Flowchart of the study
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healthcare-seeking behaviour in such patients [9]. The
delivery of CBT by telephone has been shown to be effect-
ive, acceptable and accessible [10]. The MUSICIAN study,
which we have recently concluded, tested telephone-
delivered CBT (tCBT) and/or exercise for patients with
chronic widespread pain consulting to their GP (using a 2
× 2 factorial design). Three months after the end of ther-
apy, both interventions resulted in significantly better
primary outcome measures (patient global health) than
treatment as usual (tCBT 33 % of participants with posi-
tive outcome, exercise 24 %, treatment as usual 8 %), but
there was no significant additional benefit of receiving
both interventions (combined 37 %). Recent analyses have
demonstrated these benefits are maintained 2 years after
the end of therapy (tCBT 35 % with positive outcome,
exercise 29 %, combined 31 %, treatment as usual 13 %),
and that tCBT is highly cost-effective [11].
We have conducted a comprehensive literature review
with the aim of identifying randomised trials which had
the aim of preventing the onset either of CWP or fibro-
myalgia. This review did not identify any such published
trials. Further, a search of 11 international clinical trials
registers/databases (including US, UK, Europe, Australia/
New Zealand, Japan), undertaken in Autumn 2013 did not
identify any ongoing trial with the aim of preventing the
onset of CWP (or fibromyalgia). There are several reasons
why it may be desirable to try to prevent CWP onset,
namely that the majority of CWP patients do not have im-
portant symptom improvement with current management
(even within trials). Prediction models from epidemio-
logical studies have been developed to identify “high-risk”
patients, which makes such an approach feasible. Research
using the General Practice Research Database has demon-
strated that prior to receiving a diagnosis of fibromyalgia
in primary care, persons have a long-term prior history of
consultation with symptoms [12]. Although this will be
the first prevention trial in this area, the concept of pre-
vention using CBT has been addressed in musculoskeletal
disorders with respect to intervention in neck pain and
low back pain before people become patients [13] and in
mental disorders [14].
We have conducted prospective epidemiological studies
which have demonstrated that it is possible to identify
“high-risk” groups. In the first study, a high risk group for
CWP onset was identified on the basis of two factors: som-
atic awareness (using the Somatic Symptom Scale) and
illness behaviour (using the Illness Behaviour Score) [15].
This was replicated in a second study conducted by the
applicants [16]. These “aetiological models” excluded pain
and therefore we have re-analysed data from the latter
study (also considering pain status) to identify the best pre-
dictors of onset and which results in a model more suitable
for use in prevention studies. The resulting “at risk model”
requires regional pain and two of the following: maladaptive
behavioural response to illness (Illness Behaviour score > 4),
a high number of somatic symptoms (Somatic Symptom
Score > 2) and sleep disturbance (Sleep Problem Scale
Score > 4). In the second “validation” study, from a popula-
tion of 2,374 persons without CWP, 653 satisfied the defin-
ition of “high-risk of CWP” of whom 139 had developed
CWP twelve months later (that is a Positive Predictive value
of 21.3 %). Amongst persons not deemed to be at high risk
(n = 1721), 77 developed CWP which is a Negative Predict-
ive Value of 95.5 %.
An Arthritis Research UK report on fibromyalgia/CWP,
based on a think-tank held in July 2012, identified preven-
tion as a research priority. We have previously shown short
and long-term effectiveness of tCBT for CWP (compared
to usual care), in an Arthritis Research UK funded study
[11, 17]. Specifically this demonstrated sustained improve-
ment in patient global assessment of change, reduced
psychological distress, fear of movement and reliance on
passive coping styles. Secondly we have developed and re-
fined statistical models which identify persons at high risk
for the future development of CWP. We therefore now
propose a study to test whether tCBTcan reduce the risk of
CWP onset amongst those at high risk.
We will test the hypothesis that among patients who
report regional pain for which they have already sought
a consultation in primary care, and who are identified as
high risk of developing chronic widespread pain, a short
course of telephone-delivered Cognitive Behaviour Ther-
apy (tCBT) reduces the onset of CWP. We will further
determine the cost-effectiveness of such a preventative
intervention.
Methods
Study design
The study will be a two-arm randomised controlled trial
testing a course of tCBT against usual care among patients
identified at high-risk developing CWP (Fig. 1).
Recruitment
We will mail a randomly selected sample of adults aged
25 years and over registered with participating general prac-
tices in the study areas (NHS Grampian, NHS Highland,
and NHS Greater Glasgow and Clyde). We will require the
involvement of 7 or 8 general practices. The Scottish
Primary Care Research Network (SPCRN) will be involved
in recruitment of patients to this study from primary care.
SPCRN staff will undertake searches of GPs electronic
databases to identify a random sample of potentially eligible
patients. Screening survey questionnaires will then be sent
out by Health Informatics Centre Services in Dundee on
behalf of the practice. Patients will return completed survey
questionnaires to the research team at the University of
Aberdeen where they will be assessed for eligibility and sent
letters inviting them to the trial if eligible.
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The “screening questionnaire” will determine whether
the patient a) meets the study eligibility criteria and b)
would be willing to be contacted again regarding a treat-
ment trial for “musculoskeletal health”. The questionnaire
will include:
 Pain assessed by specific questions on the experience
of pain, consultation and body manikins (which will
provide site and also allow us to exclude those who
already have chronic widespread pain)
 Illness Behaviour Scale [18]
 Somatic Symptoms Scale (excluding pain items) [19]
 Sleep Problem Scale [20]
 Quality of Life and Wellbeing (EQ-5D-5L [21];
ICECAP [22])
 General Health Questionnaire (23)
 Chalder Fatigue Scale (24)
The inclusion criteria are:
 A ‘high-risk’ profile for developing CWP as
identified on the screening survey, i.e.:
o Have pain for which they have sought
consultation to primary care in the last 6 months
o Any 2 of the following:
■ Illness Behaviour Scale Score > 4
■ Somatic Symptom Scale Score > 2
■ Sleep Problem Scale Score > 4
 Access to a landline or mobile telephone
 Ability to understand English sufficiently to
participate in the intervention
 Ability to give informed consent
 Aged 25 years or over
Exclusion criteria:
 Meeting American College of Rheumatology
definition of CWP in the 1990 criteria for
fibromyalgia (as assessed by the screening
questionnaire) [23]
 Medical conditions which would make the proposed
intervention unsuitable (e.g. cognitive ability)
 Non-availability for the intervention
A list of patients will be available to the general practi-
tioner in advance, with the option of indicating any as
unsuitable for the study. Patients would then be sent infor-
mation about the study and subsequently contacted by a
member of the research team by telephone and, if appropri-
ate, consented and recruited into the trial.
Consent
Included in the mailed invitation to eligible patients will
be an information sheet, consent form to take part in the
trial, and a best-time-to-call slip. Once a patient has
returned a signed consent form and best-time-to-call slip,
a member of the research team will phone them. The
researcher will read out from a script giving information
about the study, and the patient will have the opportunity
then to ask questions about the study. If the patient con-
sents to participate they will be recruited to the study and
randomised to one of the arms of the trial. (It is only at
this point that the participant is considered to have given
informed consent).
Randomisation
After consent has been given to participate in the study,
during the call with the participant, the researcher will
contact the Trial randomisation centre at the Centre for
Healthcare Randomised Trials at the University of Aber-
deen, using the internet or by telephone. This service is
available 24 h a day. Using a computer randomisation
program, subjects will be randomly allocated into one of
the two treatment groups, stratified in blocks by one pre-
dictor of outcome i.e. the number of non-pain “high-risk”
factors they report (2 or 3) since this is related to the risk
of CWP onset, and GP Practice. Subjects will be notified of
the outcome of allocation (i.e. to which treatment group
they have been assigned) during the consent/randomisa-
tion phone-call. If allocated to the active intervention, the
participant will receive a phone call from a therapist to
arrange an initial appointment. We will confirm the alloca-
tion to treatment arm in a letter to the participant.
Follow up
Follow-up questionnaires will be mailed to participants at
3, 12 and 24 months after the treatment start date (for
participants in the active treatment group) or dummy
treatment start date (for those in usual care). The dummy
treatment start date will be based on the treatment start
date of the last participant to be assigned to active treat-
ment. Instruments included in the follow-up question-
naires will be the same as in the screening survey
questionnaire. Additionally, follow-up questionnaires will
include the Patient Global Impression of Change (7-item
scale from “very much worse” to “very much better”), and
questions on health care usage.
Treatment protocol
The CBT intervention, delivered by telephone, will consist
of an initial assessment (45–60 min), 6 weekly sessions
(each 30–45 min) over six weeks, and then booster sessions
at 3 and 6 months. The intervention will be delivered by
therapists trained for the study and accredited by the British
Association for Behaviour and Cognitive Psychotherapies.
Participants will be supported by a self-management CBT
manual refined from the manual we developed for the
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MUSICIAN study where it was successfully used with dem-
onstrable patient benefit.
There will be a patient-centred assessment by the
therapist for problem identification, risk assessment and
development of a shared formulation of the current health
problem. The sessions will involve education about mus-
culoskeletal pain (all persons will have recently consulted
to primary care with regional pain), somatic symptoms
and specific CBT techniques such as pacing of activity,
behavioural activation, diary keeping, identifying and chal-
lenging negative and unhelpful thinking patterns and the
development of a longer term management plan. Partici-
pants’ self-management manuals will include agreed col-
laborative goals for the therapist and patient to work
towards, diaries, and some exercises to complete after
specific sessions.
Therapists delivering the intervention will receive a
2 day training programme conducted by the investigators.
Therapists will be supervised two weekly throughout the
trial period by members of the trial team. Patient adher-
ence will be examined through collecting data on number
of telephone consultations conducted and evaluation of
the use of CBT techniques through exercises contained in
the manual.
The group allocated to usual care will receive no add-
itional intervention – this will reflect the fact there is no
specific intervention provided to patients currently for the
prevention of CWP. They will receive usual care and there
will be no restriction on what this can involve. CBT within
the NHS is generally restricted to persons who have devel-
oped specific conditions rather than persons at risk of those
conditions. We will however monitor care received, outwith
the trial, in all participating subjects, and health care usage
will be recorded in follow-up.
Patient safety
There are unlikely to be major safety issues in terms of
delivery of the CBT. However, if the therapists delivering
CBT have any concerns, one of the investigators will be
available to assess these. There will be a standard tem-
plate for reporting concerns and recording of any ac-
tion recommended.
Withdrawal
Participants will have the option to withdraw from the
treatment or the study at any time. Those withdrawing
from the treatment will continue to be sent follow-up ques-
tionnaires unless they specifically request not to receive
them. Failure of any participant to complete a follow-up
questionnaire at any particular time-point will not be
counted as a withdrawal unless the participant requests not
to receive any further follow-ups.
Statistical issues
Sample size
Our previous longitudinal study of onset of CWP (and sub-
sequent replication) has suggested that 21 % of “high-risk”
persons identified will develop CWP over the course of the
next twelve months. Our previous data is based on persons
with pain and at least 2 out of 3 other “risk factors”. There
are no published studies of prevention of CWP on which to
base our measure of effect. However in the MUSICIAN
study some subjects, although reporting CWP at the
screening survey, no longer had CWP at the enrolment
interview. They were however still eligible to take part, pro-
vided they had regional pain. Therefore those subjects with
regional pain provide a sub-population on which to base
the likely effects of the tCBT. Amongst such subjects, those
who received tCBT had a reduced odds of having CWP at
the end of the study OR 0.5 95 % CI (0.2–1.4) compared to
those in usual care.
Thus the study is powered on the ability of the current
study to reduce the onset of CWP from 21 % to 12 %, with
90 % power and a 5 % significance level. We further
assume, based on prior data, that 75 % of persons allocated
to the tCBT arm will be adherent to the intervention, and
that 80 % of all subjects will return the follow-up question-
naires to assess outcome.
Accordingly we require 473 subjects per arm that is a
total of 946 subjects recruited. In MUSICIAN exactly
50 % of those found eligible and willing to consider taking
part ultimately were randomised. A previous trial of a
cognitive-behavioural intervention to prevent chronic pain
found that 36 % of patients identified as eligible were
recruited to the study [13]. If 80 % of eligible patients
agreed to be contacted about taking part, this equates to
45 % of those eligible and willing to consider taking part
being randomised - higher numbers for a clinical trial of
CWP reflect the fact that this is a prevention trial rather
than a treatment trial and may be less attractive to poten-
tial participants. Thus we aim to find a total of 2102
subjects who are eligible and willing to consider taking
part. Assuming a participation rate to the survey of 30 %,
that 1 in 4 people will be “at risk”, and (using data from
MUSICIAN) that 80 % of people who return a question-
naire agree to consider taking part, we require to survey
35 037 persons.
Statistical analysis
A pre-defined statistical analysis plan will be developed
and signed off by the trial steering committee before
undertaking any data analysis. Comparison between arms
will be on an intention-to-treat basis (main analysis) with
a per protocol sensitivity analysis.
Characteristics of the study participants in the two treat-
ment arms will be described using simple summary statis-
tics. Descriptive statistics will include mean and standard
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deviation for normally distributed continuous data, median
and inter-quartile range for skewed continuous data and
count and percentage for categorical data. No formal statis-
tical comparisons will be made between baseline character-
istics. Primary and secondary outcomes will be described at
the three follow-up times: 3, 12 and 24 months, using
appropriate summary statistics. The primary outcome is
the between arm difference in the proportions of people
developing CWP from baseline to follow-up. This compari-
son will be made using simple chi-squared tests at each
follow-up time. Appropriate adjustment will be made for
the stratification factor used in the randomisation (the
number of non-pain “high-risk” factors that a participant
reports at baseline) using multiple logistic regression.
Comparisons with appropriate hypothesis tests will be
used for the secondary outcomes, pain, illness behaviour,
somatic symptom reporting, sleep problems, quality of life
and wellbeing, psychological distress, patient global impres-
sion of change measure and fatigue. Appropriate adjust-
ment will be made for the stratification factor. Given the
multiple secondary outcomes, the p-value used to denote
statistical significance will reflect the multiple comparisons.
Mixed models analyses with an appropriate error struc-
ture will take into account the repeated assessment of the
outcome data for the same patient across the three follow-
up times. As part of sensitivity analyses, multiple imput-
ation methods will be used, where appropriate, to address
issues of missing data. However, these methods will not be
applied if the use of imputation is contrary to specified
rules for the relevant validated measurement scale.
Study management and conduct
Trial steering committee
A trial steering committee will be established and comprise
an independent chair who has expertise in both trials and
CWP and two other independent members including a
user representative who has had lived experience of CWP
and a clinician working with people with CWP.
Inspection of records
Investigators and institutions involved in the study will
permit study related monitoring and audits on behalf of the
sponsor and REC. In the event of an audit or monitoring,
the Investigator agrees to allow the representatives of the
sponsor direct access to all study records and source docu-
mentation, and participant consent will be obtained for
this.
Confidentiality
All evaluation forms, reports, and other records will be
identified in a manner designed to maintain participant
confidentiality. All records will be kept in a secure storage
area with limited access.
Data protection
All Investigators and study site staff involved with this study
will comply with the requirements of the Data Protection
Act 1998 with regard to the collection, storage, processing
and disclosure of personal information and will uphold the
Act’s core principles. Computers used to collate the data
will have limited access measures via user names and pass-
words. Published results will not contain any personal data
that could allow identification of individual participants.
Study record retention
All study documentation will be kept for a minimum of
5 years from the protocol defined end of study point.
When the minimum retention period has elapsed, study
documentation will not be destroyed without permission
from the sponsor.
End of study
The end of study is defined as data collection at 2 years
from the last participant’s date of beginning treatment
or dummy treatment start date.
Reporting, publication and notification of result
Ownership of the data arising from this study resides with
the University of Aberdeen. On completion of the study,
the study data will be analysed and tabulated, and a clinical
study report will be prepared in accordance with ICH
guidelines. The clinical study report will be used for publi-
cation and presentation at scientific meetings. Investigators
have the right to publish orally or in writing the results of
the study.
Insurance and indemnity
The University of Aberdeen is sponsoring the study. The
University of Aberdeen will obtain and hold a policy of
Public Liability Insurance of legal liabilities arising from the
study. Where the study involves University of Aberdeen
staff undertaking clinical research of NHS patients, such
staff will hold honorary contracts with Grampian Health
Board. The sponsor does not provide study participants
with indemnity in relation to participation in the study but
has insurance for legal liability as described above.
Discussion
The study will be first aimed at preventing the development
of fibromyalgia or chronic widespread pain. The results of
the study will help to inform future treatments for the
prevention of chronic pain, and aetiological models of its
development.
Ethics approval and consent to participate
The NHS Research Ethics Committee (REC)-Central Book-
ing Service (CBS) was used to book the study for full REC
review. The CBS offers the first available meeting in the
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UK, and so REC South West–Cornwall & Plymouth gave
approval to the study rather than a Scottish committee.
The study was approved by the REC South West–Cornwall
& Plymouth on 8 February 2016, and the REC Reference is
16/SW/0019. As stipulated by the ethics committee man-
agement approval from all NHS sites has been obtained.
All participants in the trial will first read an information
sheet and return by post a signed consent form, before
being contacted by a researcher by telephone and given the
opportunity to ask questions about the study and confirm
their consent to take part. Only after having both returned
a signed consent form and confirmed consent over the
phone will a person be considered as having given consent
and recruited to the trial.
Consent for publication
Not applicable.
Availability of data and material
There are no plans to place data in a repository at the
current time.
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